MannKind reported $330.85M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Adma Biologics USD 203.84M 567K Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Eli Lilly USD 54.91B 11.54B Jun/2026
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Insmed USD 544.86M 180.93M Sep/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 35.09M 1.42M Jun/2026
MannKind USD 330.85M 112K Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 233.31M 4.23M Sep/2024
Novo Nordisk DKK 146.38B 27.66B Mar/2026
Pfizer USD 62.67B 523M Sep/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Xencor USD 170.11M 5.06M Jun/2026